Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Slashes FY2021 Profit Outlook on Aduhelm Woes
May 9, 2022
- BMS Begins New PI for Compound Derived from PeptiDream Platform
May 9, 2022
- Emgality Now Available for Self-Injection in Japan: Lilly/Daiichi Sankyo
May 9, 2022
- Relugolix Approved in Europe for Prostate Cancer
May 9, 2022
- Hatsuo Aoki, Former Astellas Chair and JPMA President, Dies at 86
April 28, 2022
- Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
- Daiichi Sankyo Breaks 1 Trillion Mark in FY2021 Sales on Bullish Enhertu, Lixiana
April 28, 2022
- PharmaEssentia Submits Its 1st Drug in Japan for Polycythemia Vera
April 28, 2022
- J-TEC Files Autologous Cultured Epidermis for Stable Vitiligo; Launch Eyed in FY2023
April 28, 2022
- Enhertu Scores 5th Breakthrough Therapy Tag, This Time for HER2 Low Breast Cancer
April 28, 2022
- Kissei Files Fostamatinib, Orphan Drug for ITP, in Japan
April 28, 2022
- JCR Taps Ex-GSK Japan Chief Philippe Fauchet as Board Director
April 28, 2022
- CureApp Wins Japan Nod for Hypertension Therapeutic App, Eyes 2022 Rollout
April 28, 2022
- Pfizer’s Once-Weekly Short Stature Treatment Ngenla Now Available in Japan
April 28, 2022
- Japan Drug Makers Revving Up HR, Pay System Reforms; Eisai Mulling No Daily Allowance for Sales Reps
April 27, 2022
- Otsuka Grabs Japan Sales Rights to Cognitive Function Testing App
April 27, 2022
- Fuso Gets Japan Rights to Heart Failure Drug from Tokyo Upstart
April 27, 2022
- Shionogi Ups FY2021 Earnings Outlook on HIV Patent Suit Settlement
April 26, 2022
- Sumitomo Scraps Daily Allowance for Sales Reps, Introduces Division Bonus to Boost Productivity
April 26, 2022
- EU Panel Confirms Nod for Kissei-Originated Fibroid Drug
April 26, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…